{1}
##LOC[OK]##
{1}
##LOC[OK]##
##LOC[Cancel]##
{1}
##LOC[OK]##
##LOC[Cancel]##
Your browser does not support JavaScript or it is disabled!
Some extended features of this website cannot work without JavaScript.
Home
About Us
About Us
Team
Boards
Liver Disease
The Liver and its Functions
Liver Diseases
Treatment of Acute and Chronic Liver Disease and Cirrhosis
Further Reading
Technology
News
News
Publications
Careers
Events
Contact us
News
Publications
Careers
Events
.
Hepa Wash News
Hepa Wash Leberdialyse ist Preisträger im Wettbewerb „365 Orte im Land der Ideen"
München - Tuesday, October 25, 2011
„Hepa Wash Leberdialyse“ ist Preisträger im Wettbewerb „365 Orte im Land der Ideen“.
>>>
Hepa Wash bei den Münchner Wissenschaftstagen
München - Sunday, October 23, 2011
Die Hepa Wash GmbH präsentiert sich bei den Münchner Wissenschaftstagen mit einer Vortragreihe.
>>>
Hepa Wash GmbH closes 7 million euros financing round
Munich - Monday, July 04, 2011
The medical device company Hepa Wash GmbH, located in Munich, successfully completed a financing round acquiring a seven million euros investment in the company.
>>>
Hepa Wash certified according to ISO 13485
Munich - Wednesday, March 16, 2011
Hepa Wash is certified as medical device company according to ISO 13485 by Tüv Süd
>>>
Hepa Wash awarded ZIM Grant
Munich - Monday, January 17, 2011
Hepa Wash receives a € 125.000 grant from the Federal Ministry of Economic Affairs. The grant is paid within the central innovation program for medium-sized enterprises (ZIM) and supports the development of a production line for the fluids needed for the Hepa Wash liver support device.
>>>
Hepa Wash ranks 4th place in Eurecan European Venture Contest finale
Munich - Tuesday, December 21, 2010
Hepa Wash GmbH has ranked 4th place in the category “life sciences” in this years’ Eurecan European Venture Contest (EEVC) finale which took place on December 16th in Barcelona, Spain. The company competed with approximately 300 international companies in this category. In total nearly 1.000 companies from 24 countries participated in the three categories life sciences, information and communication technologies and clean tech. The EEVC is the largest competition of this kind worldwide.
>>>
Hepa Wash climbs next level of the Eurecan European Venture Contest
Munich - Monday, November 15, 2010
Hepa Wash GmbH is one of the semi-final winners of this year’s Eurecan European Venture Contest (EEVC). The Munich medical device company competed with over 1.000 entrepreneurs from the innovation sectors of ICT, Life Science and Cleantech from all over Europe who applied for the qualifying events of the 2010 edition of the EEVC.
>>>
Hepa Wash opens new laboratory and factory space at MTZ
Munich - Tuesday, October 12, 2010
Hepa Wash opens a new laboratory and factory space at Munich Technology Center (MTZ). In the past months on approximately 300 m² a modern equipped Research Center was established. In the new facility the preparations for the CE certification of the Hepa Wash liver dialysis device shall be completed. The Bavarian Ministry of Economic Affairs supports the further development of the innovative liver dialysis device with 770,000 euro.
>>>
Hepa Wash presents its unique liver support device at MedTech Summit 2010 in Lausanne
Munich, Germany - Wednesday, October 06, 2010
Hepa Wash GmbH was invited to showcase its patented liver support device at the MedTech Summit 2010 in Lausanne, Switzerland. For Hepa Wash the MedTech Summit is the prelude to its next financing round.
>>>
Federal Institute for Drugs and Medical Devices approves two clinical trials to evaluate the Hepa Wash liver dialysis device
Munich - Tuesday, August 03, 2010
The German Federal Institute for Drugs and Medical devices (BfArM) authorized the start of two clinical trials for a liver support therapy developed by the Munich-based medical device company Hepa Wash GmbH. The approval process examined the technical requirements as well as the plausibility of the study design. In March, Hepa Wash already received the required favorable opinion of the Ethics Committee of the hospital rechts der Isar of the Munich Technical University.
>>>
Hepa Wash closes € 3.8M Series-A financing round
Munich, Germany - Sunday, December 06, 2009
Hepa Wash GmbH (Hepa Wash) announced the successful closing of its Series-A financing round, raising €3.8m from a syndicate of new and existing private investors as well as the KfW. Hepa Wash, a medical device company developing an innovative liver assist device, announced today the closure of its € 3.8m Series-A financing round. This financing will allow Hepa Wash to develop the first generation machine to start clinical studies in spring 2010.
>>>
Hepa Wash and II. Medical Department, University Hospital Rechts der Isar Awarded € 425,000 Grant from the Bayerische Forschungsstiftung (BFS) for a € 0.9 Mio Collaborative Preclinical Study on Acute Liver Failure
Munich, Germany - Monday, April 28, 2008
Hepa Wash GmbH (Hepa Wash), a medical device company developing an innovative liver support device announced today that it has received a € 425,000 grant from the Bayerische Forschungsstiftung (BFS) to test the safety and efficacy of its laboratory prototype in a preclinical animal model for acute liver failure in collaboration with the II. Medical Department, University Hospital Rechts der Isar.
>>>
Hepa Wash Awarded BayTOU Grant
Munich, Germany - Friday, September 14, 2007
Hepa Wash GmbH (Hepa Wash), a medical device company dedicated to the development of next-generation liver support systems announced today that it has received a € 120,000 BayTOU grant from the Bavarian Government for the development of its novel and proprietary technology for the treatment of patients with liver failure.
>>>
Hepa Wash Closes Seed Financing Round of €1.1 Million
Munich, Germany - Tuesday, May 29, 2007
Hepa Wash GmbH (Hepa Wash), a medical device company dedicated to the development of next-generation liver support systems announced today the closing of a seed-financing round of €1.1 million led by a group of experienced private investors. The new funds will be used to further establish its novel and proprietary technology for the treatment of patients with liver failure and to fund animal trials.
>>>
Rss